Trial Will Test Ocrevus on Arm, Hand Function in PPMS

Trial Will Test Ocrevus on Arm, Hand Function in PPMS

303245

Trial Will Test Ocrevus on Arm, Hand Function in PPMS

A Phase 3 clinical trial testing the effect of Ocrevus (ocrelizumab) on upper limb disability progression in people with primary progressive multiple sclerosis (PPMS) is recruiting participants. The trial, called O’HAND (NCT04035005), expects to enroll approximately 1,000 adults with PPMS, ages 18 to 65, at more than 200 sites around the world. A full list of study sites and contact information is available here. Ocrevus, marketed by Genentech (part of the Roche Group), works by…

You must be logged in to read/download the full post.